Acropolis Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$443K Hold
18,379
0.02% 196
2026
Q1
$516K Buy
18,379
+21
+0.1% +$559 0.02% 178
2025
Q4
$457K Buy
18,358
+1,119
+6% +$28.2K 0.02% 181
2025
Q3
$418K Buy
17,239
+3,454
+25% +$85.3K 0.02% 187
2025
Q2
$334K Sell
13,785
-1,883
-12% -$43.9K 0.02% 184
2025
Q1
$397K Buy
15,668
+1,650
+12% +$43.2K 0.02% 167
2024
Q4
$372K Buy
14,018
+314
+2% +$8.52K 0.02% 176
2024
Q3
$397K Sell
13,704
-348
-2% -$10.2K 0.02% 163
2024
Q2
$393K Buy
14,052
+65
+0.5% +$1.79K 0.02% 159
2024
Q1
$388K Buy
13,987
+293
+2% +$8.13K 0.03% 160
2023
Q4
$394K Sell
13,694
-1,187
-8% -$35.9K 0.03% 156
2023
Q3
$494K Sell
14,881
-2,363
-14% -$83.6K 0.04% 136
2023
Q2
$633K Sell
17,244
-107
-0.6% -$4.17K 0.05% 122
2023
Q1
$708K Buy
17,351
+1,258
+8% +$54.3K 0.06% 111
2022
Q4
$825K Buy
16,093
+1,869
+13% +$89.6K 0.07% 96
2022
Q3
$622K Sell
14,224
-85
-0.6% -$4.13K 0.06% 110
2022
Q2
$750K Buy
14,309
+560
+4% +$28.5K 0.07% 99
2022
Q1
$712K Buy
13,749
+725
+6% +$37.6K 0.06% 111
2021
Q4
$769K Buy
13,024
+289
+2% +$14.3K 0.07% 101
2021
Q3
$511K Buy
12,735
+181
+1% +$8.02K 0.06% 119
2021
Q2
$492K Buy
12,554
+2
+0% +$78 0.05% 122
2021
Q1
$455K Buy
12,552
+401
+3% +$14.2K 0.05% 128
2020
Q4
$447K Buy
12,151
+120
+1% +$4.4K 0.05% 116
2020
Q3
$419K Buy
12,031
+2,746
+30% +$96.3K 0.05% 115
2020
Q2
$288K Buy
9,285
+2
+0% +$68 0.04% 129
2020
Q1
$287K Buy
9,283
+821
+10% +$28K 0.04% 118
2019
Q4
$308K Buy
8,462
+65
+0.8% +$2.31K 0.04% 120
2019
Q3
$286K Sell
8,397
-193
-2% -$7.02K 0.04% 119
2019
Q2
$353K Sell
8,590
-2,107
-20% -$83.7K 0.05% 102
2019
Q1
$431K Hold
10,697
0.07% 95
2018
Q4
$443K Buy
10,697
+369
+4% +$15.3K 0.08% 87
2018
Q3
$432K Buy
10,328
+1,486
+17% +$57.2K 0.07% 91
2018
Q2
$304K Buy
8,842
+70
+0.8% +$2.39K 0.05% 98
2018
Q1
$295K Sell
8,772
-748
-8% -$25.7K 0.05% 105
2017
Q4
$327K Buy
9,520
+2,545
+36% +$86.8K 0.05% 104
2017
Q3
$236K Buy
6,975
+1,069
+18% +$34.4K 0.04% 111
2017
Q2
$188K Buy
5,906
+371
+7% +$11.7K 0.03% 123
2017
Q1
$180K Buy
5,535
+106
+2% +$3.34K 0.03% 120
2016
Q4
$167K Sell
5,429
-2,062
-28% -$63K 0.03% 122
2016
Q3
$241K Hold
7,491
0.04% 112
2016
Q2
$250K Hold
7,491
0.05% 109
2016
Q1
$211K Buy
7,491
+108
+1% +$3.08K 0.04% 114
2015
Q4
$226K Hold
7,383
0.05% 112
2015
Q3
$220K Sell
7,383
-136
-2% -$4.36K 0.05% 111
2015
Q2
$239K Hold
7,519
0.05% 106
2015
Q1
$248K Hold
7,519
0.05% 112
2014
Q4
$222K Hold
7,519
0.04% 108
2014
Q3
$211K Hold
7,519
0.04% 113
2014
Q2
$212K Sell
7,519
-290
-4% -$8.27K 0.04% 109
2014
Q1
$238K Sell
7,809
-11,491
-60% -$343K 0.05% 104
2013
Q4
$561K Sell
19,300
-184
-0.9% -$5.36K 0.12% 75
2013
Q3
$531K Sell
19,484
-1,897
-9% -$51.6K 0.11% 82
2013
Q2
$568K Buy
+21,381
New +$591K 0.12% 73

Other funds holding PFE

Acropolis Investment Management's PFE Position: Q2 2026 in Review

Acropolis Investment Management held its Pfizer (PFE) position steady in Q2 2026 at 18,379 shares worth $443K. The position accounts for 0.02% of the portfolio, ranked #196.

Acropolis Investment Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $825K in Q4 2022. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Acropolis Investment Management held 18,379 shares of Pfizer worth $443K as of Q2 2026.
  • Acropolis Investment Management left its Pfizer share count unchanged in Q2 2026.
  • Pfizer made up 0.02% of Acropolis Investment Management's portfolio in Q2 2026, its #196 holding.
  • Acropolis Investment Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Acropolis Investment Management's Pfizer position peaked at $825K in Q4 2022.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Acropolis Investment Management's 13F filing for Q2 2026, filed 15 Jul 2026.